Yazen expands in Scandinavia through the acquisition of Danish company Medstart.

Yazen expands in Scandinavia through the acquisition of Danish company Medstart.

Yazen, the leading digital healthcare provider for obesity treatment, has acquired the Danish company Medstart. Medstart, established in Denmark and Norway, shares Yazen’s holistic approach to obesity care, making this acquisition a natural step in Yazen’s ambitious growth journey.

Medstart has successfully developed a model combining modern medications with lifestyle changes and support from multidisciplinary teams, aligning closely with Yazen’s methodology. The acquisition marks Yazen’s entry into the Danish market and strengthens its presence in Norway.

Acquisition aligned with Yazen’s growth strategy

Following Yazen’s recent completion of a €19.5 million investment round, the acquisition of Medstart aligns perfectly with the company’s expansion plans. The investment enables Yazen to further develop its offerings and expand into new markets. The Medstart acquisition is part of Yazen’s strategy to establish itself as a leading player in obesity care across Europe.

A shared goal: Enhanced obesity care

Initially, Medstart will continue to operate under its existing brand. In 2025, Yazen plans to launch its platform in the Danish market, gradually integrating Medstart into the Yazen brand. The aim is to combine the best of both worlds to create an even stronger care model.

Oliver Willacy, CEO and founder of Medstart, comments on the acquisition:
– I am impressed by Yazen’s systematic approach and their successful growth journey. Their model clearly demonstrates what is needed to make a real difference in obesity care. I look forward to becoming part of Yazen’s international team and continuing to grow and strengthen our position in the Danish market together.

Fredrik Meurling, founder and CEO of Yazen, adds:
– We are excited to work with Medstart’s skilled team and continue our shared mission of improving the lives of people with obesity. By combining our strengths, we can provide patients in Denmark and Norway with the best possible care.

A revolution in obesity care

Obesity is a chronic disease affecting millions of people and costing society enormous resources. Yazen’s model, which integrates digital care, multidisciplinary teams, and modern medications, has proven to be a groundbreaking solution for helping patients lose weight and maintain a healthy lifestyle. With over 20,000 patients treated and demonstrated effectiveness, Yazen is eager to continue making a difference in new markets.

For more information:
Fredrik Meurling, CEO Yazen: fredrik@yazen.se
Oliver Willacy, CEO Medstart: oliver@medstart.dk, +45 42831808
Fredrik Pallin, Head of PR Yazen: fredrik.pallin@yazen.com, +46 708 114 115

‍

About Yazen Health

Founded by health care professionals in Sweden in 2021, Yazen is pioneering a revolutionary approach to obesity treatment through digital healthcare. Combining groundbreaking GLP-1 and GLP-1/GIP weight loss medications with comprehensive lifestyle guidance, Yazen offers a holistic, data-driven solution. With over 20,000 active users who have collectively lost 200+ tons, Yazen stands out in treating the global obesity epidemic. Its innovative model provides personalised obesity programmes through an advanced yet user-friendly app, enhancing access to specialist care including doctors, coaches, dietitians, psychologists and physiotherapists.

‍

About Medstart

Medstart was founded by two doctors in Denmark in 2021 with the mission to combine digital health platforms, lifestyle intervention and medical weight loss treatment. The care model combines the expertise from doctors, nurses and lifestyle coaches. The company is strongly positioned in both Denmark and Norway, and have demonstrated solid results in terms of sustained weight loss.

‍